Amway’s 1Q17 revenue declined 22.5% yoy to RM237.2m due to a high base effect in 1Q16 which resulted from: i) strong buy up in 1Q16 ahead of price hikes in Feb and Apr 2016 and ii) higher sales from increased number of Amway Business Owners (ABOs) and sales incentives for its 40th anniversary programs. We also note that distribution costs spiked 14.5% yoy, constituting 5.3% of revenue from 3.6% (a 2ppts increase), reflecting the higher import costs. As a result, 1Q17 EBIT margin contracted 2.5ppts to 5% while net earnings declined 48% yoy to RM9.5m.
Revenue dropped 5.5% qoq while operational costs increased amidst elevated imports costs. As a result, earnings declined 8.8% qoq. The decline would be higher if not for lower sales incentives provisions.
We expect Amway to face a challenging year with the soft domestic economy set to prevail on the back of high cost of living impacting weak consumer sentiment. Furthermore, competition is on the rise with rising online marketing campaigns from rival brands. We believe earnings would remain under pressure going forward on higher distribution and marketing expense as it aims to boost sales. We slashed FY17/FY18/FY19 earnings by 10%/10%/9% respectively to incorporate the weaker-than-expected sales and a much higher import costs.
Amway declared a 1st single tier interim dividend of 5sen which is same as 1Q16. We estimate a total of 30sen dividend for the whole year. This translates to a dividend yield of 3.9%.
We downgrade the stock to SELL (from Hold) with a lower TP of RM6.95 (from RM8.06) which implies FY17F PE of 21.6x. Our DCF derived TP is based on WACC of 7.5% and long term growth rate of 1.5%
Source: BIMB Securities Research - 18 May 2017
Chart | Stock Name | Last | Change | Volume |
---|
Created by kltrader | Nov 12, 2024
Created by kltrader | Nov 11, 2024
Created by kltrader | Nov 11, 2024
Created by kltrader | Nov 11, 2024
Created by kltrader | Nov 08, 2024